HL Financial Services LLC Buys 1,043 Shares of Allergan PLC. (AGN)
HL Financial Services LLC increased its stake in Allergan PLC. (NYSE:AGN) by 3.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,286 shares of the company’s stock after buying an additional 1,043 shares during the period. HL Financial Services LLC’s holdings in Allergan PLC. were worth $6,876,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. GWM Advisors LLC increased its position in Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the period. Burns J W & Co. Inc. NY increased its position in Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the period. Gilder Gagnon Howe & Co. LLC increased its position in Allergan PLC. by 0.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after buying an additional 9 shares during the period. Trust Co increased its position in Allergan PLC. by 0.8% in the first quarter. Trust Co now owns 1,224 shares of the company’s stock valued at $292,000 after buying an additional 10 shares during the period. Finally, JNBA Financial Advisors increased its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.
Allergan PLC. (NYSE AGN) opened at 227.73 on Friday. The stock has a market cap of $76.13 billion, a PE ratio of 6.94 and a beta of 1.19. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The company’s 50-day moving average price is $238.12 and its 200-day moving average price is $237.88.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the business posted $3.35 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. On average, equities analysts expect that Allergan PLC. will post $16.27 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.23%. Allergan PLC.’s dividend payout ratio is currently 9.95%.
TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/02/hl-financial-services-llc-buys-1043-shares-of-allergan-plc-agn.html.
AGN has been the topic of several recent analyst reports. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a research note on Monday, June 26th. UBS AG reissued a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a research note on Monday, May 15th. Wells Fargo & Company reissued an “outperform” rating and set a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Royal Bank Of Canada lifted their target price on Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Finally, Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a research note on Wednesday, May 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company. Allergan PLC. presently has an average rating of “Buy” and a consensus target price of $275.49.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.